雪峯科技(603227.SH)2019年淨利預增84.49%至9552.18萬元
格隆匯1月23日丨雪峯科技(603227.SH)發佈2019年年度業績預告,預計2019年年度實現歸屬於上市公司股東的淨利潤約為9552.18萬元,與上年同期(法定披露數據)相比增加4374.64萬元,同比增長84.49%左右。歸屬於上市公司股東扣除非經常性損益事項後的淨利潤約為7915.58萬元,與上年同期(法定披露數據)相比增加4860.72萬元,同比增長159.11%左右。本期業績預計增加的主要原因是:經產能調整後,母公司混裝炸藥和子公司新疆雪峯爆破工程有限公司混裝炸藥產能得以釋放並在本期產生經濟效益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.